HC Wainwright Reiterates Buy Rating for Kiora Pharmaceuticals (NASDAQ:KPRX)

HC Wainwright restated their buy rating on shares of Kiora Pharmaceuticals (NASDAQ:KPRX) in a research note released on Tuesday,Benzinga reports. The firm currently has a $10.00 price objective on the stock.

Kiora Pharmaceuticals Trading Down 3.1 %

Kiora Pharmaceuticals stock opened at $3.62 on Tuesday. Kiora Pharmaceuticals has a 1 year low of $3.00 and a 1 year high of $8.98. The firm’s 50 day moving average price is $3.53 and its 200-day moving average price is $4.29.

Kiora Pharmaceuticals (NASDAQ:KPRX) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.09. On average, equities analysts forecast that Kiora Pharmaceuticals will post 1.17 EPS for the current year.

Institutional Investors Weigh In On Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC acquired a new position in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals comprises approximately 0.8% of Stonepine Capital Management LLC’s portfolio, making the stock its 16th biggest holding. Stonepine Capital Management LLC owned 6.86% of Kiora Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 76.97% of the stock is currently owned by hedge funds and other institutional investors.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.